mesowatch
HomeLawyers Dispute the $1.1 Billion Talc Settlement Increase
divider

Is J&J Playing Fair? Lawyers Dispute the $1.1 Billion Talc Settlement Increase

Is J&J Playing Fair? Lawyers Dispute the $1.1 Billion Talc Settlement Increase

On September 4, Johnson & Johnson boldly announced a $1.1 billion increase to its proposed talc settlement, This would increase the settlement to more than $9 billion paid over 25 years. The company framed this move as a development in resolving thousands of lawsuits alleging that J&J’s talc-based products caused ovarian cancer.

However, several plaintiffs’ lawyers quickly challenged this report, suggesting it was “nothing more than a misleading PR stunt” that misrepresented the true status of negotiations

Sources familiar with the plaintiff’s side dispute J&J’s portrayal of the situation, stating, ‘The statements made are inconsistent with the reality of ongoing discussions.

The sources allege that J&J’s press release grossly exaggerated the level of agreement among claimants, conveniently failing to acknowledge the numerous unresolved issues that continue to plague the settlement process.

Plaintiffs’ Firms Turn on Each Other

The situation dramatically turned on September 11 when Beasley Allen filed suit against Smith Law Firm. Beasley Allen has accused the Smith Law Firm of negotiating a deal with J&J without fully considering the interests of other plaintiffs’ firms.

Central to J&J’s strategy is the use of the controversial “Texas two-step,” a legal tactic where the company creates a subsidiary to assume its talc liabilities, which then conveniently files for bankruptcy.

While technically legal, this move has faced intense criticism from plaintiffs and legal experts who view it as a calculated attempt to minimize J&J’s financial exposure.

The $1.1 billion addition to the settlement was intended to encourage more plaintiffs to accept the terms, but it seems to have only deepened divisions and fueled further skepticism.

Was J&J Misleading the Plaintiffs?

At the core of this heated dispute is the serious accusation that J&J’s press release deliberately misled the public and plaintiffs about the progress of the settlement. Claims that the company grossly exaggerated the situation suggest an underhanded attempt to influence the narrative in its favor.

As lawsuits between plaintiffs’ firms continue to mount and questions persist about the accuracy of J&J’s public statements, the path forward for the talc settlement remains murky at best.


FAQs: J&J $1.1 Billion Talc Settlement Increase

Below are a few of the questions we commonly hear regarding the case from social media and other channels.

What is the Johnson & Johnson talc settlement about?

Johnson & Johnson is facing lawsuits alleging that its talc products, such as baby powder, contained asbestos and caused cancer. The settlement aims to resolve these lawsuits through a financial agreement.

Why did J&J increase the settlement by $1.1 billion?

J&J added $1.1 billion to the settlement to address concerns from plaintiffs and to encourage more claimants to agree to the proposed terms, bringing the total offer to $6.5 billion.

What are the plaintiffs’ lawyers saying about the settlement?

Plaintiffs’ lawyers argue that J&J’s announcement was misleading, suggesting that the company’s public statements did not reflect the true nature of the ongoing negotiations.

What is the “Texas two-step” strategy?

J&J employed the “Texas two-step” by creating a subsidiary to handle its talc liabilities, which then filed for bankruptcy. This move helps the company limit its overall financial responsibility.

What happens next in the J&J talc settlement case?

With lawsuits between plaintiffs’ firms and unresolved disputes over the settlement terms, the case is expected to involve more legal challenges before reaching any final resolution.

Matthew Davis

Reading Time: 1 mins

Published On: September 11, 2024

Matthew Davis - author

Matthew Davis is a freelance journalist who has covered civil litigation for a variety of publications. He joined Mesowatch in 2016 and covers asbestos litigation developments in the U.S., as well as newsworthy asbestos cases.

More to Read

Section Divider

Amna Anees - November 17, 2024

CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma

Mini Divider
Mesowatch Logo

Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.

NAVIGATE

About UsEditorial GuidelinesNewsSupport and ResourcesPrivacy PolicySitemap

CONTACT US

Email: support@mesowatch.com

Phone: (866) 402-1000

Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251

Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer